ESTRO IOERT工作组/ACROP推荐:乳腺癌电子术中放疗
该综述总结了电子术中放疗(IOERT)在保乳治疗中作为部分乳腺照射(PBI)和预期推量(IOERT-Boost)的应用,涵盖患者选择标准、技术要求、物理方面和结局数据。作为PBI,ELIOT随机试验显示IOERT组乳腺内复发率显著高于全乳照射(WBI),但低危患者全剂量IOERT与标准WBI等效;作为推量,ISIORT Europe汇总分析显示低危肿瘤局部复发率约1%,高危患者长期局部控制率仍超过95%。
要点
- IOERT作为PBI时,ELIOT试验显示乳腺内复发率显著高于WBI,但低危患者全剂量IOERT与WBI等效。
- 肿瘤>2cm、腋窝淋巴结阳性、Grade 3和三阴性亚型是乳腺内复发的显著预测因素。
- IOERT推量(多约10Gy)后WBI 50Gy,低危肿瘤局部复发率约1%,长期控制率>95%。
核心结论
- IOERT作为PBI在低危乳腺癌患者中与标准WBI等效,已被多个国家指南纳入标准技术之一。
- IOERT推量后WBI在低危肿瘤中局部复发率约1%,高危患者长期局部控制率仍超过95%,美容结局良好。
研究设计与样本
- 本综述为ESTRO IOERT工作组/ACROP推荐,基于意大利研究(尤其ELIOT随机试验)和ISIORT Europe汇总分析等证据。
主要发现
- ELIOT试验显示IOERT组乳腺内复发率显著高于WBI组,即使在预设等效界值内。
- 肿瘤大小>2cm、腋窝淋巴结阳性、Grade 3和三阴性分子亚型是乳腺内复发的显著预测因素。
- 低危患者全剂量IOERT与标准WBI等效。
- ISIORT Europe汇总分析中,单次推量剂量多约10Gy后WBI 50Gy常规分割,中位随访达十年,低危肿瘤局部复发率约1%。
- Grade 3、三阴性及局部晚期原发系统治疗后患者局部复发率较高,但长期(>5年)局部控制率仍超过95%。
关键数值与推荐
- IOERT作为PBI适用于ASTRO/ESTRO推荐的低危乳腺内复发患者,全剂量IOERT与标准WBI等效。
- IOERT推量单次剂量多约10Gy,后接WBI 50Gy常规分割。
临床怎么用
- 对于精心选择的低危乳腺癌患者,IOERT可作为PBI的标准技术之一。
- IOERT推量可用于预期推量,尤其低危肿瘤,局部控制率和美容结局良好。
局限性
- IOERT作为PBI时乳腺内复发率显著高于WBI,即使在预设等效界值内。
- Grade 3、三阴性及原发系统治疗后局部晚期患者局部复发率较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this review is to provide a comprehensive overview of the role of intraoperative radiation therapy with electrons (IOERT) in breast conserving therapy (BCT), both as partial breast irradiation (PBI) as well as anticipated boost ("IOERT-Boost"). For both applications, the criteria for patient selection, technical details/requirements, physical aspects and outcome data are presented. IOERT AS PBI: The largest evidence comes from Italian studies, especially the ELIOT randomized trial. Investigators showed that the rate of in-breast relapses (IBR) in the IOERT group was significantly greater than with whole breast irradiation (WBI), even when within the pre-specified equivalence margin. Tumour sizes >2 cm, involved axillary nodes, Grade 3 and triple negative molecular subtypes emerged as statistically significant predictors of IBR. For patients at low risk for in-breast recurrence (ASTRO/ESTRO recommendations), full dose IOERT was isoeffective with standard WBI. Hence, several national guidelines now include this treatment strategy as one of the standard techniques for PBI in carefully selected patients. IOERT BOOST: The largest evidence for boost IOERT preceding WBI comes from pooled analyses performed by the European Group of the International Society of Intraoperative Radiation Therapy (ISIORT Europe), where single boost doses (mostly around 10 Gy) preceded whole-breast irradiation (WBI) with 50 Gy (conventional fractionation). At median follow-up periods up to ten years, local recurrence rates around 1% were observed for low risk tumours. Higher local relapse rates were described for grade 3 tumours, triple negative breast cancer as well as for patients treated after primary systemic therapy for locally advanced tumours. Even in this settings, long-term (>5y) local tumour control rates beyond 95% were achieved. These encouraging results are interpreted as being attributable to utmost precision in dose delivery (by avoiding a "geographic and/or temporal miss"), and the possible radiobiological superiority of a single high dose fraction, compared to the conventionally fractionated boost. IOERT also showed favourable results in terms of cosmetic outcome, assumedly thanks to the small treated volumes combined with complete skin sparing.
引用
- Fastner G, Gaisberger C, Kaiser J, et al. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer. Radiother Oncol. 2020. PMID: 32413529. doi:10.1016/j.radonc.2020.04.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。